Compare VMD & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VMD | IRWD |
|---|---|---|
| Founded | 2006 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.4M | 251.8M |
| IPO Year | N/A | 2010 |
| Metric | VMD | IRWD |
|---|---|---|
| Price | $7.26 | $3.55 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.34 |
| AVG Volume (30 Days) | 146.8K | ★ 2.3M |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.92 | N/A |
| EPS | ★ 0.34 | 0.18 |
| Revenue | $254,794,000.00 | ★ $338,987,000.00 |
| Revenue This Year | $20.05 | N/A |
| Revenue Next Year | $17.44 | $4.01 |
| P/E Ratio | $21.26 | ★ $20.22 |
| Revenue Growth | ★ 18.89 | N/A |
| 52 Week Low | $5.93 | $0.53 |
| 52 Week High | $8.93 | $5.13 |
| Indicator | VMD | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 64.67 | 61.03 |
| Support Level | $6.60 | $3.50 |
| Resistance Level | $7.44 | $3.80 |
| Average True Range (ATR) | 0.20 | 0.32 |
| MACD | 0.07 | -0.05 |
| Stochastic Oscillator | 75.60 | 55.49 |
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.